Clonal evolution from primary to locally recurrent rectal cancer reveals recurrence-acquired potentially actionable alterations in treatment-naïve tumors.
{"title":"Clonal evolution from primary to locally recurrent rectal cancer reveals recurrence-acquired potentially actionable alterations in treatment-naïve tumors.","authors":"Mamoru Uemura, Yuta Kobayashi, Hisataka Ogawa, Yurika Nakamura, Masakatsu Paku, Nobuo Takiguchi, Chikako Kusunoki, Yuki Sekido, Mitsunobu Takeda, Tsuyoshi Hata, Atsushi Hamabe, Takayuki Ogino, Norikatsu Miyoshi, Yoshinori Kagawa, Mitsuyoshi Tei, Yuichiro Doki, Hidetoshi Eguchi","doi":"10.1007/s00535-026-02479-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Locally recurrent rectal cancer (LRRC) occurs in 6-10% of patients after curative surgery. It is often regarded as a simple residual disease, yet accumulating evidence suggests that LRRC is biologically distinct from primary tumors. Clonal evolution in matched primary-recurrence pairs not exposed to preoperative therapy has not been systematically investigated.</p><p><strong>Methods: </strong>We analyzed formalin-fixed paraffin-embedded tumor specimens from 15 matched pairs of primary and locally recurrent rectal cancers not exposed to preoperative therapy using targeted next-generation sequencing of 22 colorectal cancer-related genes, including TP53, KRAS, PIK3CA, MET, and FGFR family members. Tumor areas were selectively collected to ensure high tumor purity. Mutations were classified as shared or unique, and variant allele frequencies (VAFs) and clonality (VAF > 30%) were evaluated.</p><p><strong>Results: </strong>Among 415 pathogenic mutations, 12/15 pairs (80%) harbored shared driver alterations, with TP53 shared in 11 (73%). Shared mutations showed higher VAFs in recurrences than in primaries (median 57.1% vs 47.6%; p = 0.003). Unique mutations were modestly higher in recurrences (median 5.4% vs 4.8%; p = 0.048). Clonal mutations exhibited greater VAFs at recurrence (median 86.4% vs 49.8%; p = 0.048), while the numbers of clonal mutations were comparable (32 vs 32). Potentially actionable alterations involving MET and FGFR family genes were observed in recurrent lesions in a subset of cases, including some detected at clonal levels.</p><p><strong>Conclusions: </strong>LRRC is not merely residual disease but an evolutionarily progressed tumor entity characterized by persistence and dominance of truncal drivers with acquisition of clinically relevant alterations. Profiling recurrent lesions may guide therapy as primary tumor profiling alone may miss potentially actionable alterations present in recurrent lesions.</p>","PeriodicalId":16059,"journal":{"name":"Journal of Gastroenterology","volume":" ","pages":"1582-1592"},"PeriodicalIF":5.7000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695673/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00535-026-02479-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Locally recurrent rectal cancer (LRRC) occurs in 6-10% of patients after curative surgery. It is often regarded as a simple residual disease, yet accumulating evidence suggests that LRRC is biologically distinct from primary tumors. Clonal evolution in matched primary-recurrence pairs not exposed to preoperative therapy has not been systematically investigated.
Methods: We analyzed formalin-fixed paraffin-embedded tumor specimens from 15 matched pairs of primary and locally recurrent rectal cancers not exposed to preoperative therapy using targeted next-generation sequencing of 22 colorectal cancer-related genes, including TP53, KRAS, PIK3CA, MET, and FGFR family members. Tumor areas were selectively collected to ensure high tumor purity. Mutations were classified as shared or unique, and variant allele frequencies (VAFs) and clonality (VAF > 30%) were evaluated.
Results: Among 415 pathogenic mutations, 12/15 pairs (80%) harbored shared driver alterations, with TP53 shared in 11 (73%). Shared mutations showed higher VAFs in recurrences than in primaries (median 57.1% vs 47.6%; p = 0.003). Unique mutations were modestly higher in recurrences (median 5.4% vs 4.8%; p = 0.048). Clonal mutations exhibited greater VAFs at recurrence (median 86.4% vs 49.8%; p = 0.048), while the numbers of clonal mutations were comparable (32 vs 32). Potentially actionable alterations involving MET and FGFR family genes were observed in recurrent lesions in a subset of cases, including some detected at clonal levels.
Conclusions: LRRC is not merely residual disease but an evolutionarily progressed tumor entity characterized by persistence and dominance of truncal drivers with acquisition of clinically relevant alterations. Profiling recurrent lesions may guide therapy as primary tumor profiling alone may miss potentially actionable alterations present in recurrent lesions.
背景:6-10%的患者在根治性手术后发生局部复发直肠癌(LRRC)。它通常被认为是一种简单的残留疾病,但越来越多的证据表明,LRRC在生物学上与原发性肿瘤不同。未接受术前治疗的原发复发配对的克隆进化尚未系统研究。方法:我们分析了来自15对匹配的未接受术前治疗的原发性和局部复发直肠癌的福尔马林固定石蜡包埋肿瘤标本,使用了22种结直肠癌相关基因的靶向下一代测序,包括TP53、KRAS、PIK3CA、MET和FGFR家族成员。选择性采集肿瘤区域,确保肿瘤高纯度。将突变分类为共享或独特,并评估变异等位基因频率(VAFs)和克隆性(vafb0 %)。结果:在415个致病突变中,12/15对(80%)有共同的驱动基因改变,其中11对(73%)有共同的TP53基因改变。共有突变在复发患者中的VAFs高于原发患者(中位数为57.1% vs 47.6%, p = 0.003)。独特突变的复发率略高(中位数5.4% vs 4.8%; p = 0.048)。克隆突变在复发时表现出更高的VAFs(中位数为86.4% vs 49.8%; p = 0.048),而克隆突变的数量相当(32 vs 32)。在一些病例的复发性病变中,包括在克隆水平上检测到的一些病例中,观察到涉及MET和FGFR家族基因的潜在可操作的改变。结论:LRRC不仅仅是一种残留疾病,而是一种进化进展的肿瘤实体,其特征是躯干驱动因素持续存在并占主导地位,并获得临床相关的改变。分析复发病变可以指导治疗,因为单独的原发性肿瘤分析可能会错过复发病变中潜在的可操作的改变。
期刊介绍:
The Journal of Gastroenterology, which is the official publication of the Japanese Society of Gastroenterology, publishes Original Articles (Alimentary Tract/Liver, Pancreas, and Biliary Tract), Review Articles, Letters to the Editors and other articles on all aspects of the field of gastroenterology. Significant contributions relating to basic research, theory, and practice are welcomed. These publications are designed to disseminate knowledge in this field to a worldwide audience, and accordingly, its editorial board has an international membership.